If you have been reading about visceral fat and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-06. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
=== Modern history === Cannabis was introduced to the New World by the Spaniards in 1530–1545. Following an 1836–1840 travel in North Africa and the Middle East, French physician Jacques-Joseph Moreau wrote on the psychological effects of cannabis use; he founded the Paris' Club des Hashischins in 1844. In 1842, Irish physician William Brooke O'Shaughnessy, who had studied the drug while working as a medical officer in Bengal with the East India Company, brought a quantity of cannabis with him on his return to Britain, provoking renewed interest in the West. Examples of classic literature of the period featuring cannabis include Les paradis artificiels (1860) by Charles Baudelaire and The Hasheesh Eater (1857) by Fitz Hugh Ludlow.
Esimone, Charles, MI Okeke, CU Iroegbu, EN Eze, AS Okoli, "Evaluation of extracts of the root of Landolphia owerrience for antibacterial activity", Journal of ethnopharmacology 78 (2-3), 119-127 Esimone, Charles, KF Chah, CA Eze, CE Emuelosi, "Antibacterial and wound healing properties of methanolic extracts of some Nigerian medicinal plants", Journal of ethnopharmacology 104 (1-2), 164-167 Esimone, Charles, CS Nworu, CL Jackson, "Cutaneous wound healing activity of a herbal ointment containing the leaf extract of Jatropha curcas L.(Euphorbiaceae)", International Journal of Applied Research in Natural Products 1 (4), 1-4 Esimone, Charles, IR Iroha, EC Ibezim, CO Okeh, EM Okpana, "In vitro evaluation of the interaction between tea extracts and penicillin G against Staphylococcus aureus", African Journal of Biotechnology 5 (11) Esimone, Charles, PA Ekwealor, MC Ugwu, I Ezeobi, G Amalukwe, BC Ugwu, U Okezie et al., "Antimicrobial evaluation of bacterial isolates from urine specimen of patients with complaints of urinary tract infections in Awka, Nigeria", International journal of microbiology 2016 (1), 9740273
=== Repression and counter-coups === It has been argued that failed coups might motivate a regime to reform and reduce repression. Such reforms are not obvious in the data, as of 2017. Coups that fail, or merely shuffle the leadership without changing the system, generally do not change the amount of repression (measured in government-sanctioned and pro-government killings). Research from 2016 suggests that increased repression and violence typically follow both successful and unsuccessful coup attempts. According to a 2019 study, coup attempts lead to a reduction in physical integrity rights. Coups that lead to democratization unsurprisingly reduce repression, and coups that bring in a new autocratic regime increase it. Post-Cold-War, post-coup autocracies seem to have become more repressive and post-coup democracies less repressive; the gap between them is therefore larger than it was during the Cold War. Averaging across democratic and non-democratic outcomes, most coups seem to tend to increase state repression, even coups against autocrats who were already quite repressive. The time interval in which violence is measured matters. The months after a bloodless coup can be bloody. The small sample size and high variability means that this conclusion again does not reach statistical significance, and a firm conclusion cannot be drawn. According to Naunihal Singh, author of Seizing Power: The Strategic Logic of Military Coups (2014), it is "fairly rare" for the incumbent government to violently purge the army after a failed coup.
Sources: en.wikipedia.org
Edward Said asked many times, in public and private, where the Mandela of Palestine could be. In rather bold contrast to this decent imagination, Arafat managed to be both a killer and a compromiser (Mandela was neither), both a Swiss bank account artist and a populist ranter (Mandela was neither), both an Islamic "martyrdom" blow-hard and a servile opportunist, and a man who managed to establish a dictatorship over his own people before they even had a state (here one simply refuses to mention Mandela in the same breath). Hitchens had previously collaborated on this issue with Edward Said, publishing the 1988 book Blaming the Victims: Spurious Scholarship and the Palestinian Question. Hitchens had said of himself, "I am an Anti-Zionist. I'm one of those people of Jewish descent who believes that Zionism would be a mistake even if there were no Palestinians." and "If Jews born in Brooklyn have a right to a state in Palestine, then Palestinians born in Jerusalem have a right to a state in Palestine. Anyone who doesn't agree with that principle I think is suspect." A review of his autobiography Hitch-22 in The Jewish Daily Forward refers to Hitchens "at the time [that he had learned that his grandparents were Jews, he had been] a prominent anti-Zionist" and says that he viewed Zionism "as an injustice against the Palestinians". Others have commented on his anti-Zionism as well.
Hyberbaric Oxygen Therapy Wound Debridement, a minor surgical procedure enhances the growth of healthy tissues in the wound Transcutaneous Oxygen Monitoring, a test that records the level of oxygen available to your wound Doppler Evaluation of Pulses, a technique that measures the blood flow available to bring nutrients and medications to the wound
The organizers had overbooked the venue, leaving hundreds of fans locked outside. When Gillespie and Hart attempted to break the locks, the police were called. Support band Meat Whiplash had stirred up violence before the Mary Chain set foot onto the stage when singer Paul McDermott threw an empty wine bottle into the audience, prompting four members of the crowd to attack him, leading to their set being abandoned. Second act The Jasmine Minks got through their set without incident, but The Jesus and Mary Chain then kept the audience waiting for over an hour before taking the stage, and then left the stage after playing for less than twenty minutes. Members of the audience began throwing cans at where the band were hiding behind the stage curtains, before mounting the stage to smash the equipment that remained there. The violence continued for some time before police eventually took control. The venue blamed the band's late appearance and two equipment breakdowns, while McGee issued a statement saying that "the audience were not smashing up the hall, they were smashing up pop music", going on to say "This is truly art as terrorism". The violence soon started to become a hindrance to the band, with people attending concerts simply for the violence rather than the music, William commenting "I hate it, I despise it. It gets in the way in terms of getting more gigs, and it gets in the way of our image". Many performances were cancelled during the remainder of 1985, with promoters or local councils not prepared to risk a riot.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.